|Table of Contents|

Clinical observation of Shengmai injection combined with slowly continuous intravenous infusion of anthracyclines in reducing the risk of early cardiotoxicity

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 03
Page:
499-502
Research Field:
Publishing date:

Info

Title:
Clinical observation of Shengmai injection combined with slowly continuous intravenous infusion of anthracyclines in reducing the risk of early cardiotoxicity
Author(s):
JIANG Jinlong1; JI Chengfu1; HE Guangsheng2; SUN Naitong3
1.Department of Hematology，Funing County People's Hospital, Jiangsu Funing 224400，China；2.Department of Hematology，Jiangsu Provincial People's Hospital，Jiangsu Nanjing 210029，China；3.Department of Hematology，Third People's Hospital of Yancheng City，Jiangsu Yancheng 224006，China.
Keywords:
Shengmai injection; intravenous infusion; anthracyclines; cardiotoxicity
PACS:
R733.72
DOI:
DOI：10.3969/j.issn.1672-4992.2021.03.030
Abstract:
Objective：To observe the clinical effects of Shengmai injection combined with slowly continuous intravenous infusion of anthracyclines in reducing the risk of early cardiotoxicity.Methods：68 cases of patients with acute leukemia were selected from the department of hematology of People' s Hospital of Funing County，Jiangsu Provincial People' s Hospital and Yancheng Third People' s Hospital during the period from January 2016 to April 2018.They were grouped according to the treatment method.38 cases treated with Shengmai injection combined with slowly continuous intravenous infusion of anthracyclines were included in the observation group，and 30 cases treated with conventional intravenous infusion of anthracyclines without Shengmai injection were included in the control group.The occurrence of abnormal electrocardiogram(ECG) and changes of cardiac color Doppler ultrasound and related test indicators before and after treatment were compared between the two groups.Results：The incidence rates of abnormal ECG such as ST-T changes，QT interval prolongation，nodal tachycardia and arrhythmia in observation group were lower than those in control group(P<0.05).At 8d after treatment，the normal rate of cTnI in observation group was significantly higher than that in control group while the abnormal rate was significantly lower than that in control group(P<0.05).The LVEF level in observation group after treatment was higher than that in control group while the BNP level was lower than that in control group(P<0.05).Conclusion：Shengmai injection combined with slowly continuous intravenous infusion of anthracyclines can protect cardiomyocytes，improve myocardial metabolism and reduce myocardial damage，thus reducing the incidence rate of early cardiotoxicity.

References:

[1]吕跃，侯健，纪春岩，等.中国蒽环类药物在白血病治疗中的临床应用专家共识［J］.中国肿瘤临床，2018，45(3)：117-119. LYU Yue，HOU Jian，JI Chunyan，et al.Expert consensus on the clinical application of Chinese anthracyclines in the treatment of leukemia［J］.Cancer Clinical of China，2018，45(3)：117-119.
[2]王琳，杨雪，肖玲芳，等.蒽环类药物心脏毒性分析及临床使用建议［J］.中国现代医学杂志，2017，27(12)：101-105. WANG Lin，YANG Xue，XIAO Lingfang，et al.Cardiac toxicity analysis of anthracyclines and suggestions for clinical use［J］.Chinese Journal of Modern Medicine，2017，27(12)：101-105.
[3]贺飞，薄明明，梁锌，等.蒽环类药物致乳腺癌患者急性心脏毒性的发生及影响因素的回顾性研究［J］.中国药学杂志，2017，52(12)：1089-1092. HE Fei，BO Mingming，LIANG Xin，et al.A retrospective study on the occurrence and influencing factors of acute cardiotoxicity in breast cancer patients induced by anthracyclines［J］.Chinese Journal of Pharmacy，2017，52(12)：1089-1092.
[4]王巍，李政，李康.益气养心汤在乳腺癌辅助化疗中预防蒽环类药物心脏毒性的临床作用研究［J］.中华中医药学刊，2015，33(10)：2535-2537. WANG Wei，LI Zheng，LI Kang.Yiqi Yangxin Decoction in the prevention of anthracycline cardiotoxicity in breast cancer adjuvant chemotherapy［J］.Chinese Journal of Traditional Chinese Medicine，2015，33(10)：2535-2537.
[5]徐心.心肌细胞损伤的特异性标志-心肌钙蛋白I［J］.医学综述，2002，8(12)：701-702. XU Xin.Cardiac troponin I a specific marker of myocardial cell damage［J］.Medical Review，2002，8(12)：701-702.
[6]陈晓娟，邹尧，杨文钰，等.CCLG-ALL2008方案治疗儿童急性淋巴细胞白血病复发患儿的特征分析［J］.中国当代儿科杂志，2015，17(4)：321-326. CHEN Xiaojuan，ZOU Yao，YANG Wenyu，et al.Characteristic analysis of CCLG-ALL 2008 regimen in children with relapsed acute lymphoblastic leukemia［J］.Chinese Journal of Pediatrics，2015，17(4)：321-326.
[7]李菊，朱艳.急性早幼粒细胞白血病患者初治死亡的临床分析［J］.重庆医学，2017，46(26)：3716-3718. LI Ju，ZHU Yan.Clinical analysis of initial death in patients with acute promyelocytic leukemia［J］.Chongqing Medical College，2017，46(26)：3716-3718.
[8]齐宇新，刘姣，何颖娜，等.乳腺癌术后蒽环类化疗药物致心脏损害的早期监测分析［J］.中国药房，2017，28(17)：2356-2359. QI Yuxin，LIU Jiao，HE Yingna，et al.Early monitoring and analysis of cardiac damage caused by anthracycline chemotherapeutic drugs after breast cancer surgery［J］.Chinese Pharmacy，2017，28(17)：2356-2359.
[9]CORREMANS R，ADO R.Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity［J］.Clinical and Experimental Pharmacology & Physiology，2018，46(3)：204-215.
[10]余炜，郭增清，谢瑞祥，等.右丙亚胺联合参麦注射液用于蒽环类药物致乳腺癌患者心脏毒性的临床观察［J］.中国药房，2015，26(32)：4562-4564. YU Wei，GUO Zengqing，XIE Ruixiang，et al.Clinical observation on cardiotoxicity of dextran combined with Shenmai injection in breast cancer patients induced by anthracyclines［J］.Chinese Pharmacy，2015，26(32)：4562-4564.
[11]KOUTSOUKIS A，NTALIANIS A，REPASOS E，et al.Cardio-oncology：A focus on cardiotoxicity［J］.European Cardiology，2018，13(1)：64-69.
[12]曲敬琨，张佳，张靖，等.蒽环类药物心脏毒性防治药物研究进展［J］.中国肿瘤临床，2014，41(22)：1474-1477. QU Jingkun，ZHANG Jia，ZHANG Jing，et al.Advances in the study of anthracycline drugs for cardiotoxicity prevention and treatment［J］.Cancer Clinical of China，2014，41(22)：1474-1477.
[13]郭琳娟，俞建华，李菊香，等.持续静脉缓慢滴注和静脉推注降低蒽环类药物心脏毒性风险的荟萃分析［J］.临床心血管病杂志，2017，33(1)：34-39. GUO Linjuan，YU Jianhua，LI Juxiang，et al.Meta-analysis of the risk reduction of anthracycline cardiotoxicity by continuous slow intravenous drip and intravenous injection［J］.Journal of Clinical Cardiovascular Disease，2017，33(1)：34-39.
[14]YEUNG TK，CHAKRABARTI K，WILDING D，et al.Modification of doxorubicin-induced cardiotoxicity：Manipulation of the dosage schedule［J］.Human & Experimental Toxicology，2002，21(11)：607.
[15]马增春，肖勇，赵佳伟，等.人参皂苷Re对H9c2心肌细胞CYP450酶的影响［J］.中国药理学通报，2016，32(4)：494-498. MA Zengchun，XIAO Yong，ZHAO Jiawei，et al.Effects of ginsenoside Re on CYP450 enzymes in H9c2 myocardial cells［J］.Chinese Pharmacological Bulletin，2016，32(4)：494-498.
[16]李靳，邓丽丽，周志勇，等.三七总皂苷联合淫羊藿总黄酮改善D-gal致H9c2大鼠心肌细胞衰老的保护作用［J］.中国中药杂志，2017，42(3)：555-561. LI Jin，DENG Lili，ZHOU Zhiyong，et al.Panax notoginseng saponins combined with total flavonoids of Herba Epimedii improve the protective effect of D-gal on myocardial cell senescence induced by H9c2 in rats［J］.Chinese Journal of Traditional Chinese Medicine，2017，42(3)：555-561.
[17]汪艳群，孟宪军.超声波处理对北五味子多糖抗氧化活性的影响［J］.食品科学，2016，37(3)：66-70. WANG Yanqun，MENG Xianjun.Effects of ultrasound treatment on antioxidant activity of Schisandra chinensis polysaccharides［J］.Food Science，2016，37(3)：66-70.
[18]FAROLFI A，MELEGARI E，AQUILINA M，et al.Trastuzumab-induced cardiotoxicity in early breast cancer patients：A retrospective study of possible risk and protective factors［J］.Heart，2013，99(9)：634-639.
[19]MANTARRO S，ROSSI M，BONIFAZI M，et al.Risk of severe cardiotoxicity following treatment with trastuzumab：A meta-analysis of randomized and cohort studies of 29 000 women with breast cancer［J］.Internal & Emergency Medicine，2015，11(1)：123-140.
[20]BONIFAZI M，FRANCHI M，ROSSI M，et al.Trastuzumab-related cardiotoxicity in early breast cancer：A cohort study［J］.Oncologist，2013，18(7)：795-801.
[21]AN J，SHEIKH MS.Toxicology of trastuzumab：An insight into mechanisms of cardiotoxicity［J］.Current Cancer Drug Targets，2019，19(5)：400-407.

Memo

Memo:
-
Last Update: 2021-01-02